Punjab University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, Lahore, 54000, Pakistan.
Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Jail Road, Lahore, Pakistan.
AAPS PharmSciTech. 2021 Feb 9;22(2):68. doi: 10.1208/s12249-021-01938-7.
Poor physicomechanical properties and limited aqueous solubility restrict the bioavailability of aceclofenac when given orally. To improve its above properties, aceclofenac (ACE) was cocrystallized with dimethyl urea (DMU) in 1:2 molar ratio by dry and solvent assisted grinding. The cocrystals were characterized by ATR-FTIR, DSC, and PXRD, and their surface morphology was studied by SEM. There was enhancement in intrinsic dissolution rate (IDR) (eight- and ~fivefold in cocrystals prepared by solvent assisted grinding (SAG) and solid state grinding (SSG), respectively, in 0.1 N HCl, pH 1.2) and similarly (3.42-fold and 1.20-fold in phosphate buffer, pH 7.4) as compared to pure drug. Additionally, mechanical properties were assessed by tabletability curves. The tensile strength of ACE was < 1 MPa in contrast to the cocrystal tensile strength (3.5 MPa) which was ~1.98 times higher at 6000 psi. The tablet formulation of cocrystal by direct compression displayed enhanced dissolution profile (36% in 0.1 N HCl, pH 1.2, and 100% in phosphate buffer, pH 7.4) in comparison to physical mixture ( 30% and ~ 80%) and ACE (~18% and ~50%) after 60 min, respectively. Stability studies of cocrystal tablets for 3 months indicated a stable formulation. Pharmacokinetic studies were performed by using rabbit model. The AUC (37.87±1.3 μgh/ml) and C (6.94±2.94 μg/ml) of the selected cocrystal C1 prepared by SAG were significantly enhanced (p < 0.05) and were ~3.43 and ~1.63-fold higher than that of ACE. In conclusion, new cocrystal of ACE-DMU was successfully prepared with improved tabletability, in vitro and in vivo properties.
当口服给予时,较差的物理机械性能和有限的水溶解度限制了醋氯芬酸的生物利用度。为了改善其上述性能,将醋氯芬酸(ACE)与二甲基脲(DMU)以 1:2 的摩尔比通过干法和溶剂辅助研磨进行共晶化。共晶通过 ATR-FTIR、DSC 和 PXRD 进行表征,并通过 SEM 研究其表面形态。内在溶解速率(IDR)得到提高(在 0.1N HCl 中,通过溶剂辅助研磨(SAG)和固态研磨(SSG)制备的共晶分别提高了约 8 倍和 5 倍,在 pH 1.2 时;在磷酸盐缓冲液中相似,提高了约 3.42 倍和 1.20 倍,在 pH 7.4 时)与纯药物相比。此外,通过片剂可压性曲线评估机械性能。与共晶的拉伸强度(3.5MPa)相比,ACE 的拉伸强度<1MPa(在 6000psi 时高 1.98 倍)。直接压缩共晶的片剂配方显示出与物理混合物(0.1N HCl,pH1.2 时约 36%,磷酸盐缓冲液,pH7.4 时约 100%)和 ACE(0.1N HCl,pH1.2 时约 18%,磷酸盐缓冲液,pH7.4 时约 50%)相比,释放曲线得到了增强,分别在 60 分钟后。共晶片剂的 3 个月稳定性研究表明配方稳定。使用兔模型进行药代动力学研究。通过 SAG 制备的选定共晶 C1 的 AUC(37.87±1.3μgh/ml)和 C(6.94±2.94μg/ml)显著提高(p<0.05),分别是 ACE 的约 3.43 倍和 1.63 倍。总之,成功制备了具有改善的可压性、体外和体内性质的 ACE-DMU 新共晶。